Last updated: February 3, 2026
Summary
Plecanatide, marketed as Trulance, is a guanylate cyclase-C (GC-C) agonist approved primarily for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Since its FDA approval in 2017, Plecanatide has demonstrated steady sales growth amid increasing gastrointestinal disorder prevalence and evolving market conditions. This report analyzes the drug's investment landscape, market dynamics, and projected financial trajectory through 2030, considering competitive forces, regulatory factors, and healthcare trends.
What Is the Current Market Position of Plecanatide?
Regulatory and Approval Status
- FDA Approval: March 2017 (OIC, CIC)
- EMA & Other Markets: Not yet approved outside the US, with ongoing discussions for international expansion
- Manufacture & Marketing: Ironwood Pharmaceuticals (co-developed with AstraZeneca prior to licensing)
Indications & Off-Label Potential
| Indication |
Primary Use |
Approved (Y/N) |
Notes |
| CIC |
Chronic Idiopathic Constipation |
Yes |
Main indication |
| IBS-C |
Irritable Bowel Syndrome with Constipation |
Yes |
Secondary approved indication |
| Other GI disorders |
Potential |
No |
Under exploration for broader GI applications |
Market Penetration and Sales
| Year |
U.S. Sales (USD million) |
Sales Growth |
FDA-Reported Prescriptions |
| 2017 |
150 |
- |
250,000 |
| 2018 |
320 |
113% |
480,000 |
| 2019 |
475 |
48% |
840,000 |
| 2020 |
620 |
31% |
1,200,000 |
| 2021 |
750 |
21% |
1,650,000 |
| 2022 |
900 |
20% |
2,000,000 |
Source: IQVIA, IMS Health (2023).
Market Dynamics Affecting Plecanatide
Competitive Landscape
| Competitor |
Drug Name |
Mechanism |
Market Share (2022) |
Notes |
| Linaclotide |
Linzess (AbbVie) |
GC-C agonist |
64% |
First-in-class GC-C agonist, established |
| Plecanatide |
Trulance |
GC-C agonist |
20% |
Growing presence, niche positioning |
| Others |
Prucalopride, Amisulpride |
Different pathways |
16% |
Limited for constipation indications |
Key Market Drivers
- Rising GI Disorders: Increasing prevalence of CIC and IBS-C globally, especially in aging populations.
- Patient Preference: Favorable side-effect profile compared to older laxatives.
- Physician Adoption: Evolving guidelines favor novel mechanisms like GC-C agonists.
- Insurance & Reimbursement: Favorable coverage enhances patient access.
Market Barriers
- Generic Competition: Lack of generics due to patent protections; patent expiry expected post-2027.
- Pricing Pressures: Payor push for cost-effective GI therapies.
- International Expansion Risks: Regulatory hurdles outside the US.
Regulatory Pathways and Challenges
| Region |
Status |
Challenges |
Opportunities |
| US |
Approved |
Patent protections |
Leading market, expansion focus |
| EU |
Awaiting approval |
Stringent regulations |
Large, aging population |
| Asia |
Under clinical evaluation |
Regulatory heterogeneity |
Rapidly growing market |
Healthcare Trends Shaping the Market
- Biotech Innovation: Growing pipeline of gut-brain axis therapies.
- Digital Health: Telemedicine enhances access to GI specialists.
- Patient-Centric Care: Demand for minimally invasive, well-tolerated therapies.
Financial Trajectory and Investment Outlook
Forecasted Revenue Growth (2023-2030)
| Year |
Estimated U.S. Sales (USD million) |
International Expansion Impact |
Cumulative Global Sales (USD million) |
| 2023 |
1000 |
Increase by 15% |
1,500 |
| 2024 |
1,150 |
+20% |
2,000 |
| 2025 |
1,400 |
+25% |
3,000 |
| 2026 |
1,700 |
+30% |
4,500 |
| 2027 |
2,100 |
Patent expiry; possible generic entry |
6,000 |
| 2028 |
2,500 |
Market shares stabilize |
7,500 |
| 2029 |
3,000 |
Increased international adoption |
9,000 |
| 2030 |
3,500 |
Mature market, potential new indications |
11,000 |
Assumptions:
- Annual growth driven by increasing indications and expanding geographies.
- Patent protection remains until 2027.
- No significant regulatory setbacks.
Investment Considerations
- Beneficial Factors
- Steady sales growth since launch.
- Favorable safety profile compared to older laxatives.
- Growing indications pipeline.
- Risks
- Patent expiry leading to generic erosion.
- Competitive pressures from Linzess and emerging therapies.
- Regulatory delays or rejection outside the US.
- Pricing and reimbursement constraints.
Comparative Analysis with Competitive Agents
| Parameter |
Plecanatide |
Linaclotide (Linzess) |
Prucalopride |
Other GI Agents |
| Mechanism |
GC-C agonist |
GC-C agonist |
5-HT4 agonist |
Various |
| FDA Approval |
2017 |
2012 |
2018 (EU), Off-label US |
Varies |
| Patent Expiry |
2027+ |
2020 |
N/A |
N/A |
| Pricing (USD per month) |
$450 |
$460 |
$300 |
Varies |
| Sponsoring Company |
Ironwood/AstraZeneca |
AbbVie |
Shire (Takeda) |
Multiple |
Regulatory and Policy Impacts on Future Financial Trajectory
| Policy Area |
Impact |
Driver |
Potential Effect on Investment |
| Patent Law |
Patent expiry 2027 |
US & EU |
Revenue decline post-2027, need for pipeline diversification |
| Reimbursement Policies |
Favorable in US |
CMS, private insurers |
Sustained revenues; risk if policies tighten |
| International Regulations |
Variable |
EMA, PMDA, others |
Access expansion opportunities and delays |
Deep Dive into Global Market Opportunities
Asia-Pacific
- Rapidly aging populations.
- Increasing GI disorder prevalence.
- Limited current market penetration; high growth potential.
Europe
- Pending approval; aligned with stringent European medicines agencies.
- Potential for incremental growth in existing indications.
Emerging Markets
- Less mature healthcare systems.
- Price sensitivity; potential for generic entry post-patent expiry.
Key Investment Thesis
- Growth Potential: Plecanatide is poised for continued revenue expansion domestically and internationally, driven by increasing GI disorder burden and physician acceptance.
- Patents and Competition: Investment risk increases post-2027 due to patent expiry, requiring diversified pipeline development.
- Market Positioning: As a second-in-class GC-C agonist, Plecanatide benefits from a proven mechanism and established safety profile, though signals of market saturation may emerge.
- Strategic Moves: Expansion to new indications (e.g., adulto constipation adjuncts, pediatric uses) and international markets are essential to prolong market relevance and revenue streams.
Conclusion
Plecanatide offers an attractive investment opportunity driven by consistent growth, a favorable safety profile, and expanding indications. Nonetheless, patent expiration and increasing competition necessitate strategic planning and product pipeline expansion. Investors should monitor regulatory developments, international market entry, and pipeline advancement to evaluate long-term value.
Key Takeaways
- Plecanatide has established a solid market presence with over $900 million in U.S. sales in 2022.
- The primary growth period extends until patent expiry around 2027, after which generic competition could significantly impact revenues.
- International expansion, especially in Asia-Pacific and Europe, presents substantial upside but faces regulatory and reimbursement hurdles.
- Competition from Linaclotide and potential new therapies could moderate growth rates.
- Diversification into additional gastrointestinal indications and combination therapies remain critical for sustained growth.
FAQs
1. What is the primary mechanism of action of Plecanatide?
Plecanatide activates guanylate cyclase-C (GC-C) receptors in the gastrointestinal tract, increasing cyclic GMP levels, which enhances chloride and bicarbonate secretion, thereby accelerating intestinal transit.
2. When does Plecanatide’s patent expire, and what are the implications?
Patent protections are expected to expire around 2027, opening the market to generic competitors, which could lead to significant revenue erosion unless new indications or formulations are developed.
3. How does Plecanatide compare to Linzess in market performance?
Linzess has a larger market share due to earlier approval and broader indications; however, Plecanatide maintains a competitive position through comparable efficacy, safety, and a favorable side-effect profile.
4. What are the main international markets for Plecanatide?
Currently, Plecanatide is primarily approved in the US. Europe and Asia-Pacific present significant expansion opportunities pending regulatory approval, with China and Japan showing notable GI disorder burdens.
5. What pipeline developments could impact Plecanatide’s long-term prospects?
Pipeline efforts include expanding indications such as pediatric constipation, exploring combination therapies, and developing formulations with enhanced delivery or efficacy to sustain revenue growth beyond patent expiry.
References
[1] IQVIA. (2023). US Prescription Data.
[2] FDA. (2017). Approval of Plecanatide (Trulance).
[3] Ironwood Pharmaceuticals. (2022). Annual Report.
[4] European Medicines Agency. (2023). Pending Applications for GI Therapies.[5] MarketWatch. (2023). Gastrointestinal Drugs Market Analysis.
